Peter B.
- Country
- Belgium
- Department
- Gastroenterology
Research Overview
- Evaluation of Transmural Healing as a Treatment Target in Moderately to Severely Active Crohn's Disease Using Upadacitinib, Risankizumab, and Ustekinumab
- Efficacy and Safety of Risankizumab as Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis: A Randomized, Double-Blind, Placebo-Controlled Study
- Efficacy and Safety of Risankizumab in Maintenance and Long-term Extension for Moderately to Severely Active Crohn's Disease: A Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 114 of 310 partner sites.
Specializations
Inflammatory Bowel Disease Management
This investigator specializes in the treatment of inflammatory bowel diseases, with particular emphasis on both Crohn's disease and ulcerative colitis. Their research encompasses comprehensive disease management approaches and innovative therapeutic strategies.
- Advanced therapeutic approaches for Crohn's disease
- Ulcerative colitis treatment optimization
- Inflammatory bowel disease type unclassified (IBDU)
Treatment Innovation
The investigator focuses on evaluating novel therapeutic agents, including targeted therapies and biological treatments. Their work includes assessment of medications such as mirikizumab, risankizumab, and infliximab for inflammatory bowel conditions.
- Long-term efficacy evaluation
- Therapeutic drug monitoring
- Treatment optimization strategies
Clinical Outcomes Research
Their research examines various clinical endpoints including transmural healing, endoscopic remission, and histological remission. The investigator studies treatment targets and their impact on disease outcomes.
- Disease remission assessment
- Biomarker evaluation
- Long-term disease management
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.